BioWorld

March 19, 2018

When tech and health merge, how will life sciences prevail?

The line between health care and technology is becoming blurred. Read More

Tracking public companies focused on hot therapeutic markets

Biopharmaceutical companies had no difficulty attracting capital in 2017. In fact, they raised $52 billion – an amount that places the year solidly in second place in terms of annual totals generated by the industry. Read More

Word on the street

Week in Washington

Regulatory submissions, approvals and other actions: February 2018

Money raised by biotech: 2018 vs. 2017

Money raised by biotech: Jan. 1 - March 8, 2018

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Week in review

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...